Open access
Open access
Powered by Google Translator Translator

Covid-19

WHO Guidance for surveillance of SARS-CoV-2 variants.

11 Aug, 2021 | 08:50h | UTC

Guidance for surveillance of SARS-CoV-2 variants: Interim guidance, 9 August 2021 – World Health Organization

 

Commentary on Twitter (thread – click for more)

 

M-A: More than 50 long-term effects of COVID-19.

11 Aug, 2021 | 08:47h | UTC

More than 50 long-term effects of COVID-19: a systematic review and meta-analysis – Scientific Reports

Related:

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Cohort study: Risk factors for long covid in previously hospitalized children.

Viewpoint: The road to addressing Long Covid.

Review: Long covid—mechanisms, risk factors, and management.

Review: Symptoms, complications and management of long COVID.

Long Covid: fatigue, post-exertional malaise, and cognitive dysfunction are the most common symptoms, according to an international survey.

Studies elucidate poorly understood long COVID.

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Long Covid: 39% of patients report persistent symptoms more than seven months after diagnosis of COVID-19 in an outpatient setting.

[Preprint] Long Covid: Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people.

Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms.

Long Covid: Half of young adults with COVID-19 have persistent symptoms 6 months after, study finds.

[Preprint] Long Covid: Third of people infected have long term symptoms.

Opinion | Causation or confounding: why controls are critical for characterizing long COVID – “Many of the self-reported symptoms, such as intermittent headaches or tiredness, are nonspecific and prevalent in the general population”.

Almost 25% of COVID-19 patients develop long-lasting symptoms, according to a new report.

Perspective | The four most urgent questions about long COVID.

Systematic review: Frequency, signs and symptoms, and criteria adopted for long COVID-19.

Report: 376,000 people in UK have had long Covid symptoms for at least a year.

Systematic review of 45 studies including 9751 participants, most of which were hospitalized, found 73% had at least 1 persistent symptom for weeks after Covid-19.

COVID Morbidity – The emerging burden of long COVID is significant, and needs to be considered when evaluating the risk vs. benefit of pandemic measures.

One year after hospital discharge due to SARS-CoV-2 Infection, the prevalence of long-term cough, chest pain, dyspnea, and fatigue was 2.5%, 6.5%, 23.3%, and 61.2%, respectively

Population-based cohort study: Non-hospitalized COVID-19 patients have low-risk of serious long-term effects, but visits to general practitioners and outpatient hospital visits are increased.

One third of patients hospitalized with COVID-19 have lung changes after a year

Long Covid: Largest post-acute COVID-19 study to date examined the health outcomes in more than 73,000 people who’d had COVID-19 and were not hospitalized

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Perspective | They Tested Negative for Covid. Still, They Have Long Covid Symptoms.

Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditions

Cohort study: One in ten have long-term effects 8 months following mild COVID-19

Long Covid Implications for the workplace

Long Covid in the UK – More than a million affected in February, survey suggests

Covid-19: Middle aged women face greater risk of debilitating long term symptoms

Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers”

Opinion | We need to start thinking more critically — and speaking more cautiously — about long Covid

Review | Post-acute COVID-19 syndrome

Long Covid | Four-month clinical status of a cohort of patients after hospitalization for COVID-19

Perspective | Long Covid isn’t as unique as we thought

Attributes and predictors of long COVID

WHO Report: Preparing for Long COVID 2021

Long Covid: Sequelae in adults at 6 Months after COVID-19 infection

How many people get ‘long COVID’ – and who is most at risk?

Long Covid: Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge

Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline

Patients, clinicians seek answers to the mystery of ‘Long COVID’

Long Covid: 6-month consequences of COVID-19 in patients discharged from hospital

[Preprint] Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact

NICE Guideline: Managing the long-term effects of COVID-19

 

Commentary on Twitter

 

Opinion | We should not dismiss the possibility of eradicating COVID-19: comparisons with smallpox and polio.

11 Aug, 2021 | 08:42h | UTC

We should not dismiss the possibility of eradicating COVID-19: comparisons with smallpox and polio – BMJ Global Health

News release: Global eradication of COVID-19 probably feasible, and more so than for polio, say public health experts – British Medical Journal

 

CDC Report: COVID-19 morbidity and mortality far exceed the potential risks of rare side effects caused by vaccines.

11 Aug, 2021 | 08:45h | UTC

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021 – CDC Morbidity and Mortality Weekly Report

 

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

11 Aug, 2021 | 08:44h | UTC

Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine–Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review – JAMA Cardiology

Related:

NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)

 

Commentary on Twitter

 

M-A: Child and youth mental health problems have doubled during COVID-19.

10 Aug, 2021 | 10:03h | UTC

Commentary: Child and youth mental health problems have doubled during COVID-19 – The Conversation

Original study: Global Prevalence of Depressive and Anxiety Symptoms in Children and Adolescents During COVID-19: A Meta-analysis – JAMA Pediatrics

Editorial: Addressing the Global Crisis of Child and Adolescent Mental Health – JAMA Pediatrics

Related:

More data on the harmful effects of the COVID-19 pandemic on the mental health of adolescents.

COVID has caused ‘mass trauma,’ worsening mental health globally.

COVID’s mental-health toll: how scientists are tracking a surge in depression

CDC Report: Mental health-related emergency department visits among children aged under 18 years raised during the COVID-19 Pandemic

WHO: COVID-19 disrupting mental health services in most countries

 

Commentary on Twitter (thread – click for more)

 

[Preprint] Phase 1/2 RCT: A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac.

10 Aug, 2021 | 09:58h | UTC

A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – medRxiv

 

Commentary on Twitter

 

Viral load of SARS-CoV-2 in respiratory aerosols emitted by COVID-19 patients while breathing, talking, and singing.

10 Aug, 2021 | 10:02h | UTC

Viral Load of SARS-CoV-2 in Respiratory Aerosols Emitted by COVID-19 Patients while Breathing, Talking, and Singing – Clinical Infectious Diseases

 

Commentary on Twitter

 

A WHO expert explains why she believes the rush for Covid-19 boosters is premature.

10 Aug, 2021 | 09:56h | UTC

A WHO expert explains why she believes the rush for Covid-19 boosters is premature – STAT

 

Commentary on Twitter

 

Covid-19: How effective are vaccines against the delta variant?

10 Aug, 2021 | 10:00h | UTC

Covid-19: How effective are vaccines against the delta variant? – The BMJ

 

A giant trial of COVID-19 treatments organized by the WHO is restarting. Here are the drugs it’s betting on.

10 Aug, 2021 | 09:52h | UTC

A giant trial of COVID-19 treatments is restarting. Here are the drugs it’s betting on – Science

Related: WHO Solidarity trial to restart with focus on drugs that act on immune responses caused by Covid-19.

 

Study ties COVID vaccines to lower transmission rates.

10 Aug, 2021 | 09:51h | UTC

Study ties COVID vaccines to lower transmission rates – CIDRAP

Original study: Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021 – Eurosurveillance

 

‘Breakthrough’ infections do not mean COVID vaccines are failing.

10 Aug, 2021 | 09:54h | UTC

‘Breakthrough’ Infections Do Not Mean COVID Vaccines Are Failing – Scientific American

 

Commentary on Twitter

 

Interactive infographic: Data shows how rare severe breakthrough Covid infections are.

9 Aug, 2021 | 00:01h | UTC

Data shows how rare severe breakthrough Covid infections are – NBC News

 

Commentary on Twitter

 

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

9 Aug, 2021 | 00:06h | UTC

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial – The Lancet

Invited commentary: Optimising SARS-CoV-2 vaccination schedules – The Lancet

Related: Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (several articles on the subject)

 

Commentary on Twitter

 

COVID: WHO calls for moratorium on booster shots – is it justifiable?

8 Aug, 2021 | 23:54h | UTC

COVID: WHO calls for moratorium on booster shots – is it justifiable? – The Conversation

Related: Covid: WHO calls for booster pause to vaccinate poorer nations.

 

Commentary on Twitter

 

CDC study showed a reduced risk of reinfection with SARS-CoV-2 after covid-19 vaccination.

9 Aug, 2021 | 00:03h | UTC

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021 – CDC Morbidity and Mortality Weekly Report

 

Commentaries on Twitter

 

M-A: SARS-CoV-2 Setting-specific transmission rates – “Households showed the highest transmission rates, with a pooled secondary attack rates of 21.1%”.

8 Aug, 2021 | 23:57h | UTC

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Setting-specific Transmission Rates: A Systematic Review and Meta-analysis – Clinical Infectious Diseases

 

Commentary on Twitter

 

COVID vaccine boosters: the most important questions.

8 Aug, 2021 | 23:52h | UTC

COVID vaccine boosters: the most important questions – Nature

 

Commentary on Twitter

 

Tokyo feared Games would spread COVID; numbers suggest that didn’t happen.

8 Aug, 2021 | 23:56h | UTC

Tokyo feared Games would spread COVID; numbers suggest that didn’t happen – Reuters

 

Commentary on Twitter

 

More data showing one dose of Pfizer vaccine may be enough for individuals who’ve had COVID.

8 Aug, 2021 | 23:50h | UTC

Commentary: One Dose of Pfizer Vaccine May Be Enough for Folks Who’ve Had COVID – HealthDay

Original Study: SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine – JAMA Network Open

Related:

Perspective | Is one vaccine dose enough if you’ve had COVID? What the science says.

Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19

Spain to give just one vaccine dose to under 55-year olds who had COVID-19

Perspective: Is one vaccine dose enough after COVID-19 infection?

France’s health authority recommends single vaccine shot for people who have had COVID-19

Covid-19: People who have had infection might only need one dose of mRNA vaccine

 

Commentary on Twitter

 

Case report: Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford–AstraZeneca) vaccination.

8 Aug, 2021 | 23:49h | UTC

Systemic capillary leak syndrome afer ChAdOx1 nCOV-19 (Oxford–AstraZeneca) vaccination – Canadian Medical Association Journal

 

[Preprint] RCT: non-invasive respiratory strategies in acute respiratory failure in patients with COVID-19 – CPAP reduced the composite outcome of intubation or death within 30 days; high-flow nasal oxygenation was not associated with better outcomes.

6 Aug, 2021 | 10:18h | UTC

An adaptive randomized controlled trial of non-invasive respiratory strategies in acute respiratory failure patients with COVID-19 – medRxiv

Commentary: Covid: Pressured oxygen reduces ventilator need – BBC

 

Commentary on Twitter (thread – click for more)

 

Systematic Review: “Remdesivir probably has little or no effect on all‐cause mortality at up to 28 days in hospitalized adults with SARS‐CoV‐2 infection. We are uncertain about the effects of remdesivir on clinical improvement and worsening”.

6 Aug, 2021 | 10:15h | UTC

Remdesivir for the treatment of COVID‐19 – Cochrane Library

Summary: Remdesivir for the treatment of COVID-19 – Cochrane Library

 

Commentary on Twitter (thread – click for more)

 

Flawed ivermectin preprint highlights challenges of COVID drug studies.

6 Aug, 2021 | 10:07h | UTC

Flawed ivermectin preprint highlights challenges of COVID drug studies – Nature

Related:

Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.

Why was a major study on ivermectin for covid-19 just retracted?

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.